# US 2024/0082154 A1 · Disease-site-specific liposomal formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0082154 A1
- Document ID: US20240082154A1
- Status: Published application
- Kind: A1
- Application number: 18/491,953
- Filed: 2023-10-23
- Published: 2024-03-14
- Earliest claimed: 2020-05-26
- Assignees: Osaka University; Cuorips Inc.
- Applicants: Osaka University; Cuorips Inc
- Inventors: Yoshiki Sawa; Shigeru Miyagawa; Yoshiki Sakai; Yasuhiro Yanagi
- Web page: https://patentgrep.com/patent/US20240082154A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/5585: having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.

## Claims

### Claim 1

A method for treating an ischemic organ disorder comprising administering a pharmaceutical composition into a subject, wherein the pharmaceutical composition comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein, wherein the stealth liposome has an average particle size of 50 to 200 nm, and comprises 5 to 50 parts by weight of a phospholipid and 0.05 to 5 parts by weight of PEG-modified phosphoethanolamine, per part by weight of the prostaglandin I2 receptor agonist.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the prostaglandin I2 receptor agonist includes at least
a compound represented by formula (I):
wherein
is
in which e represents an integer of 3 to 5, f represents an integer of 1 to 3, p represents an integer of 1 to 4, q represents 1 or 2, and r represents an integer of 1 to 3;
R1 represents a hydrogen atom or a C1-4 alkyl group;
R2 represents (i) a hydrogen atom, (ii) a C1-8 alkyl group, (iii) a phenyl group or a C4-7 cycloalkyl group, (iv) a 4- to 7-membered monocyclic ring containing one nitrogen atom, (v) a C1-4 alkyl group substituted with a benzene ring or a C4-7 cycloalkyl group, or (vi) a C1-4 alkyl group substituted with a 4- to 7-membered monocyclic ring containing one nitrogen atom; and
R3 represents (i) a C1-8 alkyl group, (ii) a phenyl group or a C4-7 cycloalkyl group, (iii) a 4- to 7-membered monocyclic ring containing one nitrogen atom, (iv) a C1-4 alkyl group substituted with a benzene ring or a C4-7 cycloalkyl group, or (v) a C1-4 alkyl group substituted with a 4- to 7-membered monocyclic ring containing one nitrogen atom;
provided that when
is a group represented by (iii) or (iv), —(C—(CH2)p— and ═CH—(CH2)s— are bound to position a or b on the ring, and cyclic structures in R2 and R3 are optionally substituted with one to three C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, nitro groups, or trihalomethyl groups; or
a salt thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the prostaglandin I2 receptor agonist includes at least the following compound (A):
(A) ({5-[2-({[(1E)-phenyl(pyridin-3-yl)methylene]amino}oxy)ethyl]-7,8-dihydronaphthalen-1-yl}oxy)acetic acid (ONO-1301) represented by formula (II):
or a salt of compound (A).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the prostaglandin I2 receptor agonist includes at least one of the following compounds (B) to (E):
(B) sodium (±)-(1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butanoate (beraprost), or a derivative thereof that is a carbacyclic PGI2 derivative,
(C) [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid (MRE-269),
(D) (2E)-7-{(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxycyclopentyl}hept-2-enoic acid (limaprost), omoprostil, enprostil, or misoprostol; or a derivative of any of these compounds that is a PEF derivative, and
(E) 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide (NS-304; selexipag);
or
a salt of any of compounds (B) to (E).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the prostaglandin I2 receptor agonist includes at least one member selected from the group consisting of ONO-1301, beraprost, limaprost, and NS-304.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the stealth liposome is obtainable by using at least a prostaglandin I2 receptor agonist and a phospholipid by the Bangham method, hydration dispersion method, reverse phase evaporation method, ethanol injection method, ethanol dilution method, homogenization method, mechanochemical method, direct dispersion method, extruder method, French press method, remote loading method, dehydration-rehydration method, freeze-thaw method, ultrasonic method, or lipid-compound film method; or an improved method of any of these methods.

### Claim 7 (depends on 1)

The method according to claim 1,
wherein the stealth liposome comprises 0.05 to 5 parts by weight of MPEG2000-DSPE per part by weight of the prostaglandin I2 receptor agonist;
the prostaglandin I2 receptor agonist includes at least one member selected from the group consisting of ONO-1301, beraprost, limaprost, and NS-304; and
the stealth liposome releases the prostaglandin I2 receptor agonist over a period of 3 hours to 4 weeks.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the stealth liposome comprises
a prostaglandin I2 receptor agonist,
a phospholipid,
a PEG-modified phosphoethanolamine, and
a water-miscible organic solvent, and
does not comprise a sterol;
the liposome is obtainable by a production method comprising the following steps (1) to (8):
(1) mixing the prostaglandin I2 receptor agonist, the phospholipid, and the PEG-modified phosphoethanolamine in the solvent in amounts such that at least 5 mg of the phospholipid and at least 0.05 mg of the PEG-modified phosphoethanolamine are present per mg of the prostaglandin I2 receptor agonist,
(2) heating the mixture obtained in step (1) to prepare a melt,
(3) instantly freezing the melt obtained in step (2),
(4) freeze-drying the frozen product obtained in step (3) to remove the solvent,
(5) heating the freeze-dried product obtained in step (4) to disperse the heated product in an aqueous phosphate buffer solution,
(6) sizing the dispersion obtained in step (5) with an extruder,
(7) ultrafiltrating the dispersion obtained in step (6) to remove unencapsulated material, and
(8) adding a sugar to the dispersion obtained in step (7) and freeze-drying the dispersion; and
the liposome contains at least 0.001 mg of the prostaglandin I2 receptor agonist per 1.0 mg of the phospholipid, and has an average particle size of 50 to 200 nm.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition is for intravenous administration, intracoronary administration, inhalation, intramuscular administration, subcutaneous administration, oral administration, transmucosal administration, transdermal administration, or an internal organ, and is in the form of an injectable formulation, an oral preparation, an inhalant, a nebulizer, an ointment, a patch, or a spray.

### Claim 10 (depends on 1)

The method according to claim 1, wherein a single intravenous dose of the composition is 0.001 to 100 mg in terms of the prostaglandin I2 receptor agonist.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the stealth liposome is obtainable by using at least a prostaglandin I2 receptor agonist and a phospholipid by the Bangham method, hydration dispersion method, reverse phase evaporation method, ethanol injection method, ethanol dilution method, homogenization method, mechanochemical method, direct dispersion method, extruder method, French press method, remote loading method, dehydration-rehydration method, freeze-thaw method, ultrasonic method, or lipid-compound film method; or an improved method of any of these methods.

### Claim 12 (depends on 3)

The method according to claim 3, wherein the stealth liposome is obtainable by using at least a prostaglandin I2 receptor agonist and a phospholipid by the Bangham method, hydration dispersion method, reverse phase evaporation method, ethanol injection method, ethanol dilution method, homogenization method, mechanochemical method, direct dispersion method, extruder method, French press method, remote loading method, dehydration-rehydration method, freeze-thaw method, ultrasonic method, or lipid-compound film method; or an improved method of any of these methods.

### Claim 13 (depends on 4)

The method according to claim 4, wherein the stealth liposome is obtainable by using at least a prostaglandin I2 receptor agonist and a phospholipid by the Bangham method, hydration dispersion method, reverse phase evaporation method, ethanol injection method, ethanol dilution method, homogenization method, mechanochemical method, direct dispersion method, extruder method, French press method, remote loading method, dehydration-rehydration method, freeze-thaw method, ultrasonic method, or lipid-compound film method; or an improved method of any of these methods.

### Claim 14 (depends on 5)

The method according to claim 5, wherein the stealth liposome is obtainable by using at least a prostaglandin I2 receptor agonist and a phospholipid by the Bangham method, hydration dispersion method, reverse phase evaporation method, ethanol injection method, ethanol dilution method, homogenization method, mechanochemical method, direct dispersion method, extruder method, French press method, remote loading method, dehydration-rehydration method, freeze-thaw method, ultrasonic method, or lipid-compound film method; or an improved method of any of these methods.
